Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Allergan44 enrolled

Overview

The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Choroidal Neovascularization Age-Related Maculopathy

Interventions

dexamethasoneDRUG

700 µg dexamethasone intravitreal injection at Day 1 in the study eye.

ranibizumabBIOLOGICAL

Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 50 years of age or older with active subfoveal choroidal neovascularization (CNV) secondary to AMD * Central retinal thickness ≥ 300 µm * Visual acuity between 20/400 and 20/32 * Eligible for Anti-VEGF therapy Exclusion Criteria: * Previous treatment for CNV due to AMD * High eye pressure * Glaucoma * Uncontrolled systemic disease * Known allergy to the study medications * Recent eye surgery or injections in the eye * Female subjects that are of childbearing potential

Locations (3)

Unnamed facility

San Antonio, Texas, United States

Unnamed facility

Sydney, New South Wales, Australia

Unnamed facility

Manila, Philippines

Outcomes

Primary Outcomes

Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4

Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed on the study eye after pupil dilation at baseline and Week 4.

Time frame: Baseline, Week 4

Secondary Outcomes

Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 26

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

Time frame: Baseline, Week 26

Percentage of Participants With Fluorescein Leakage Improved, Unchanged and Worsened From Baseline as Assessed by Fluorescein Angiography at Week 26

Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA at Week 26 was compared to FA at Baseline. The percentage of participants in each of the following categories is reported: Improved (Leakage area decreased \>=10%), Unchanged (Leakage area changed \< 10%) and Worsened (Leakage area increased \>=10%).

Time frame: Baseline, Week 26

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.